EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) shares were up 13.6% during mid-day trading on Tuesday . The company traded as high as $7.59 and last traded at $7.39. Approximately 316,922 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 834,465 shares. The stock had previously closed at $6.50.
Wall Street Analyst Weigh In
EYPT has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Robert W. Baird cut their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research note on Monday, November 11th. Finally, Chardan Capital restated a "buy" rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $26.63.
Read Our Latest Research Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Price Performance
The company has a fifty day moving average of $7.50 and a two-hundred day moving average of $8.62. The stock has a market capitalization of $421.17 million, a P/E ratio of -3.09 and a beta of 1.51.
Institutional Investors Weigh In On EyePoint Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new stake in EyePoint Pharmaceuticals during the fourth quarter valued at about $23,705,000. TCG Crossover Management LLC grew its stake in EyePoint Pharmaceuticals by 287.3% in the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after purchasing an additional 2,650,000 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in EyePoint Pharmaceuticals by 51.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock worth $42,838,000 after buying an additional 1,958,580 shares during the last quarter. Federated Hermes Inc. grew its position in EyePoint Pharmaceuticals by 92.7% in the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after acquiring an additional 1,783,765 shares in the last quarter. Finally, Suvretta Capital Management LLC raised its holdings in shares of EyePoint Pharmaceuticals by 31.1% during the 4th quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock valued at $50,534,000 after purchasing an additional 1,607,268 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.
EyePoint Pharmaceuticals Company Profile
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Read More
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
